Studies Highlight Advances in RSV Prevention and Vaccination

Recent studies highlight the rising concern of respiratory syncytial virus (RSV) infections, particularly among children and older adults. Research by Melody Duvall indicates that severe RSV infections are linked to a decrease in natural killer (NK) cells, which could offer insights into immune system dysregulation during such infections. Additionally, a new drug, nirsevimab, has shown a 93% effectiveness in preventing hospitalizations for RSV among young children, though its uptake remains low. Vaccination rates for RSV among US adults aged 60 and older were reported at just over 22%, showing significant racial and socioeconomic disparities. Experts emphasize that the RSV vaccine is crucial for preventing severe complications in older adults, especially those with comorbid conditions. The findings underscore the need for improved vaccination strategies and public health initiatives to combat RSV.